A Retroprogesterone, 6-dehydro- CEP of the European Pharmacopoeia monograph is often referred to as a Retroprogesterone, 6-dehydro- Certificate of Suitability (COS). The purpose of a Retroprogesterone, 6-dehydro- CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Retroprogesterone, 6-dehydro- EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Retroprogesterone, 6-dehydro- to their clients by showing that a Retroprogesterone, 6-dehydro- CEP has been issued for it. The manufacturer submits a Retroprogesterone, 6-dehydro- CEP (COS) as part of the market authorization procedure, and it takes on the role of a Retroprogesterone, 6-dehydro- CEP holder for the record. Additionally, the data presented in the Retroprogesterone, 6-dehydro- CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Retroprogesterone, 6-dehydro- DMF.
A Retroprogesterone, 6-dehydro- CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Retroprogesterone, 6-dehydro- CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Retroprogesterone, 6-dehydro- suppliers with CEP (COS) on PharmaCompass.